Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2026 08:07 ET | Source: Vanderbilt Report and Artelo Biosciences

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Artelo Biosciences (NASDAQ: ARTL) enters ophthalmology space with a fully funded evaluating ART27.13 in glaucoma patients.
March 02, 2026 08:30 ET | Source: Biomimetic Innovations Ltd

Biomimetic Innovations Ltd Announces Upcoming Clinical Study of OsStic™ Injectable Synthetic Bone Void Filler in Tibial Plateau Fracture Fixation

SHANNON, Ireland, March 02, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed, an Irish medical device company specialising in biomimetic materials, today announced...
February 20, 2026 03:00 ET | Source: Onco3R Therapeutics BV

O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated

Data from the first in human study on O3R-5671’s potent TNFα inhibition Studies in ulcerative colitis and psoriasis to initiate in H2 2026 Leuven, Belgium. February 20, 2025. Onco3R Therapeutics, a...
January 27, 2026 08:00 ET | Source: Science 37, Inc.

Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation

Kelly McKee to help shape Science 37’s future patient experience, driving growth through modernized trials, innovation, and cross-team collaboration.
January 22, 2026 12:00 ET | Source: 4D Path

4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer

4D Path to participate as exploratory biomarker collaborator in Phase II DAD-IO clinical study (NCT04724018) led by DFCI and supported by Gilead Sciences
January 19, 2026 04:02 ET | Source: Nxera Pharma

Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of...
January 08, 2026 02:00 ET | Source: Tensive

Tensive reports positive pivotal trial top-line results showing REGENERA™ bioresorbable device may transform breast reconstruction

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance...
January 06, 2026 11:30 ET | Source: A Race Against Blindness

A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

GILBERT, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, today announced $1.1 million...
December 03, 2025 03:00 ET | Source: Onco3R Therapeutics BV

Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671

Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long half-life and low intersubject variability ...
November 12, 2025 08:17 ET | Source: X9, Inc.

X9, Inc. Announces Successful Completion of First-in-Human Feasibility Study for Ultrasound-Guided, Power-Assisted Needle Insertion Device in Hemodialysis Cannulation

X9, Inc. Announces Successful Completion of First-in-Human Feasibility Study for Ultrasound-Guided, Power-Assisted Needle Insertion Device in Hemodialysis.